The Promise and Pitfalls of Digital Medication
Publication/Creation DateJuly 18 2019
In November 2017, the FDA approved the Abilify MyCite system. This drug-device combination product consists of aripiprazole tablets with an ingestible event marker (IEM) sensor and a wearable sensor patch that detects the signal from the IEM sensor after ingestion, which in turn transmits data to a smartphone application. Patients can use a Web-based portal to allow monitoring by healthcare professionals and caregivers for the purpose of tracking drug ingestion and adherence. Although this new digital technology provides a means to potentially enhance adherence and yield better patient health outcomes, ethical issues may arise for both patients and providers. US Pharm. 2019;44(7):22-24.
Date archivedJuly 4 2020
Last editedJuly 20 2020